Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Plus Therapeutics, Inc.

Market Cap 34.48M 29.7M 27.35M 25.64M 48.13M 3.28B 48.69M 324M 126M 1.59B 129M 127M 5.51B P/E Ratio 2026 *
-1.28x
P/E Ratio 2027 * -2.09x
Enterprise Value 34.48M 29.7M 27.35M 25.64M 48.13M 3.28B 48.69M 324M 126M 1.59B 129M 127M 5.51B EV / Sales 2026 *
5.48x
EV / Sales 2027 * 1.8x
Free-Float
98.37%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Plus Therapeutics, Inc.

1 day-7.56%
1 week-7.39%
Current month-13.92%
1 month-12.11%
3 months-19.84%
6 months-70.69%
Current year-60.88%
1 week 5
Extreme 5
5.86
1 month 5
Extreme 5
7.3
Current year 2.9
Extreme 2.9
15.32
1 year 2.9
Extreme 2.9
23.42
3 years 2.9
Extreme 2.9
80.25
5 years 2.9
Extreme 2.9
1,087.5
10 years 2.9
Extreme 2.9
429,377.68
Manager TitleAgeSince
Chief Executive Officer 64 02/04/2014
Director of Finance/CFO 52 06/02/2020
Chief Tech/Sci/R&D Officer - 21/10/2025
Director TitleAgeSince
Director/Board Member 64 01/10/2002
Chairman 77 25/01/2018
Director/Board Member 66 01/01/2020
Date Insider Type Main position Quantity % Market Cap.
05-14Free

Chief Financial Officer

6,886 0.1003%
05-14Free

Director

7,372 0.1074%
05-14Free

Chairman

7,372 0.1074%
Change 5-day change 1-year change 3-year change Capi.($)
-7.56%-7.39%-36.18%-94.07% 34.48M
-0.35%+0.97%-13.80%-13.25% 43.03B
+3.11%+3.11%+279.08%+501.52% 32.71B
+0.22%-1.08%+15.66%-15.65% 30.29B
+1.62%-2.08%-1.91%+24.64% 29.4B
+4.09%+0.93%+12.97%+20.22% 25.08B
+1.14%+3.62% - - 13.54B
-1.63%+2.88%+56.69%+113.41% 13.35B
-0.40%-1.29%+6.23%+7.63% 12.97B
-0.74%-1.62%+105.89%+74.92% 12.11B
Average -0.05%+0.56%+47.18%+68.82% 21.25B
Weighted average by Cap. +1.05%+1.48%+57.28%+96.05%

Financials

2026 *2027 *
Net sales 6.3M 5.42M 4.99M 4.68M 8.79M 599M 8.89M 59.14M 22.99M 291M 23.62M 23.12M 1.01B 19.14M 16.48M 15.18M 14.23M 26.72M 1.82B 27.02M 180M 69.9M 885M 71.83M 70.3M 3.06B
Net income -26.8M -23.08M -21.25M -19.93M -37.41M -2.55B -37.84M -252M -97.88M -1.24B -101M -98.43M -4.28B -18.45M -15.89M -14.63M -13.72M -25.76M -1.76B -26.05M -173M -67.4M -853M -69.25M -67.78M -2.95B
Net Debt - -
Logo Plus Therapeutics, Inc.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Employees
28
Date Price Change Volume
12/06/26 5.010 $ -7.56% 98,603
11/06/26 5.420 $ +0.56% 76,745
10/06/26 5.390 $ -2.00% 126,285
09/06/26 5.500 $ -0.54% 108,493
08/06/26 5.530 $ +2.22% 145,129
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.010USD
Average target price
36.00USD
Spread / Average Target
+618.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSTV Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!